Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 8/20 | 0.67 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.63 |
| ▸ | ACE | P12821 | 2/20 | 0.57 |
| ▸ | NMBR | P28336 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21641790 | 0.97 | NLN (0.66) | GHSRNLNACENMBR | |
| SCHEMBL21641789 | 0.95 | NLN (0.69) | GHSRNLNACENMBR | |
| SCHEMBL14345559 | 0.90 | GHSR (0.64) | GHSRNLNNMBR | |
| SCHEMBL12228541 | 0.90 | GHSR (0.64) | GHSRNLNNMBR | |
| SCHEMBL30862451 | 0.89 | ACE (0.69) | ACE | |
| SCHEMBL30862455 | 0.89 | ACE (0.69) | ACE | |
| SCHEMBL30526218 | 0.89 | ACE (0.69) | ACE | |
| SCHEMBL9868128 | 0.89 | ACE (0.69) | ACE | |
| SCHEMBL30862445 | 0.89 | ACE (0.69) | ACE | |
| SCHEMBL30862460 | 0.89 | ACE (0.69) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240219403-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-04 | — | — | US | claimed |
| CN-114099713-B | Molecular probe for in vivo detection of CDK4/6 kinase activity and application thereof | 厦门大学附属翔安医院 | 2023-09-01 | — | — | CN | claimed |
| WO-2022217073-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-10-13 | — | — | WO | claimed |
| CN-114099713-A | Molecular probe for in vivo detection of CDK4/6 kinase activity and application thereof | 厦门大学附属翔安医院 | 2022-03-01 | — | — | CN | claimed |
| EP-4661892-A1 | TNF-ALPHA BINDING AGENTS AND METHODS OF USING THE SAME | Navigen, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| CN-119613494-B | Antioxidant peptide derived from fruit bodies of oleaginous bacteria, antioxidant peptide detection reagent and application | 吉林农业大学 | 2025-05-27 | — | — | CN | disclosed |
| CN-119613494-A | Antioxidant peptide derived from fruit bodies of oleaginous bacteria, antioxidant peptide detection reagent and application | 吉林农业大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-118956800-A | Polypeptide for treating brain glioma, fusion polypeptide and application of fusion polypeptide | 徐州医科大学 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024168055-A1 | TNF-ALPHA BINDING AGENTS AND METHODS OF USING THE SAME | NAVIGEN, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240219403-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-04 | — | — | US | disclosed |
| CN-117599014-A | Tryptophan dipeptide based self-assembled nano composition and preparation method and application thereof | 赣州和美药业股份有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20230381378-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMPLANT ASSOCIATED COMPLICATIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-11-30 | — | — | US | disclosed |
| CN-114099713-B | Molecular probe for in vivo detection of CDK4/6 kinase activity and application thereof | 厦门大学附属翔安医院 | 2023-09-01 | — | — | CN | disclosed |
| US-11685725-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| CN-115554413-A | Tryptophan dipeptide-based self-assembly nano composition and preparation method and application thereof | 南开大学 | 2023-01-03 | — | — | CN | disclosed |
| WO-2022217073-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022076700-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMPLANT ASSOCIATED COMPLICATIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-114099713-A | Molecular probe for in vivo detection of CDK4/6 kinase activity and application thereof | 厦门大学附属翔安医院 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685725-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | YAP1, YES1, MYC | GHSR 3879/4885NLN 4063/4885ACE 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.